Lupin, Mylan launch arthritis drug Nepexto in Germany
The product is available as an injectable in an easy-to-use pre- filled pen and a pre-filled syringe.;
Advertisement
New Delhi : Drugmaker Lupin on Wednesday said it has in association with Mylan NV launched a biosimilar product Nepexto for the treatment of rheumatoid arthritis in Germany.
Nepexto, which has been approved for all therapeutic indications of the reference product Enbrel, is indicated for the treatment of rheumatoid arthritis, severe axial spondyloarthritis and plaque psoriasis.
The product is available as an injectable in an easy-to-use pre-filled pen and a pre-filled syringe.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.